nodes	percent_of_prediction	percent_of_DWPC	metapath
Ethosuximide—CYP3A4—bone cancer	0.883	1	CbGaD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00772	0.103	CbGpPWpGaD
Ethosuximide—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00686	0.0918	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—T—bone cancer	0.00593	0.0794	CbGpPWpGaD
Ethosuximide—CYP3A43—Xenobiotics—CYP3A4—bone cancer	0.00373	0.0499	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP4V2—bone cancer	0.00332	0.0445	CbGpPWpGaD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00311	0.0416	CbGpPWpGaD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00225	0.0302	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00225	0.0301	CbGpPWpGaD
Ethosuximide—CYP3A43—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00155	0.0207	CbGpPWpGaD
Ethosuximide—CYP3A43—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00153	0.0204	CbGpPWpGaD
Ethosuximide—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.0015	0.0201	CbGpPWpGaD
Ethosuximide—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00144	0.0193	CbGpPWpGaD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.00134	0.0179	CbGpPWpGaD
Ethosuximide—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.0013	0.0174	CbGpPWpGaD
Ethosuximide—CYP3A43—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00125	0.0168	CbGpPWpGaD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00122	0.0163	CbGpPWpGaD
Ethosuximide—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00113	0.0151	CbGpPWpGaD
Ethosuximide—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.00109	0.0146	CbGpPWpGaD
Ethosuximide—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.00108	0.0145	CbGpPWpGaD
Ethosuximide—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.00105	0.014	CbGpPWpGaD
Ethosuximide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00105	0.014	CbGpPWpGaD
Ethosuximide—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.00104	0.014	CbGpPWpGaD
Ethosuximide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000983	0.0132	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000969	0.013	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000967	0.0129	CbGpPWpGaD
Ethosuximide—Hiccups—Cisplatin—bone cancer	0.00094	0.0225	CcSEcCtD
Ethosuximide—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000745	0.00997	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000713	0.00955	CbGpPWpGaD
Ethosuximide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000711	0.00952	CbGpPWpGaD
Ethosuximide—CYP3A43—Biological oxidations—CYP3A4—bone cancer	0.000666	0.00892	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—CYP3A4—bone cancer	0.000657	0.0088	CbGpPWpGaD
Ethosuximide—Vaginal haemorrhage—Epirubicin—bone cancer	0.000652	0.0156	CcSEcCtD
Ethosuximide—Irritability—Cisplatin—bone cancer	0.000652	0.0156	CcSEcCtD
Ethosuximide—Rash erythematous—Epirubicin—bone cancer	0.000631	0.0151	CcSEcCtD
Ethosuximide—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000623	0.00834	CbGpPWpGaD
Ethosuximide—Breast disorder—Cisplatin—bone cancer	0.000617	0.0147	CcSEcCtD
Ethosuximide—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000615	0.00823	CbGpPWpGaD
Ethosuximide—Cramp muscle—Cisplatin—bone cancer	0.000615	0.0147	CcSEcCtD
Ethosuximide—Vaginal haemorrhage—Doxorubicin—bone cancer	0.000604	0.0144	CcSEcCtD
Ethosuximide—Rash erythematous—Doxorubicin—bone cancer	0.000584	0.0139	CcSEcCtD
Ethosuximide—CYP3A43—Biological oxidations—GSTP1—bone cancer	0.00057	0.00763	CbGpPWpGaD
Ethosuximide—Abdominal discomfort—Cisplatin—bone cancer	0.000566	0.0135	CcSEcCtD
Ethosuximide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000565	0.00756	CbGpPWpGaD
Ethosuximide—CYP3A43—Metapathway biotransformation—GSTP1—bone cancer	0.000562	0.00752	CbGpPWpGaD
Ethosuximide—Pancytopenia—Cisplatin—bone cancer	0.00056	0.0134	CcSEcCtD
Ethosuximide—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000558	0.00747	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000551	0.00737	CbGpPWpGaD
Ethosuximide—CACNA1G—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000536	0.00717	CbGpPWpGaD
Ethosuximide—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000505	0.00676	CbGpPWpGaD
Ethosuximide—Aplastic anaemia—Methotrexate—bone cancer	0.000485	0.0116	CcSEcCtD
Ethosuximide—Hiccups—Epirubicin—bone cancer	0.000483	0.0115	CcSEcCtD
Ethosuximide—Urinary tract disorder—Cisplatin—bone cancer	0.000466	0.0111	CcSEcCtD
Ethosuximide—Connective tissue disorder—Cisplatin—bone cancer	0.000464	0.0111	CcSEcCtD
Ethosuximide—Urethral disorder—Cisplatin—bone cancer	0.000463	0.0111	CcSEcCtD
Ethosuximide—Aplastic anaemia—Epirubicin—bone cancer	0.000453	0.0108	CcSEcCtD
Ethosuximide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000451	0.00604	CbGpPWpGaD
Ethosuximide—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00045	0.00603	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.00045	0.00602	CbGpPWpGaD
Ethosuximide—Hiccups—Doxorubicin—bone cancer	0.000447	0.0107	CcSEcCtD
Ethosuximide—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000445	0.00596	CbGpPWpGaD
Ethosuximide—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000445	0.00595	CbGpPWpGaD
Ethosuximide—Eye disorder—Cisplatin—bone cancer	0.000441	0.0106	CcSEcCtD
Ethosuximide—Immune system disorder—Cisplatin—bone cancer	0.000427	0.0102	CcSEcCtD
Ethosuximide—Mediastinal disorder—Cisplatin—bone cancer	0.000426	0.0102	CcSEcCtD
Ethosuximide—Aplastic anaemia—Doxorubicin—bone cancer	0.00042	0.01	CcSEcCtD
Ethosuximide—Mental disability—Epirubicin—bone cancer	0.000419	0.01	CcSEcCtD
Ethosuximide—Malnutrition—Cisplatin—bone cancer	0.000411	0.00983	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—NDUFA12—bone cancer	0.000399	0.00535	CbGpPWpGaD
Ethosuximide—Muscle spasms—Cisplatin—bone cancer	0.000395	0.00945	CcSEcCtD
Ethosuximide—Mental disability—Doxorubicin—bone cancer	0.000388	0.00927	CcSEcCtD
Ethosuximide—Lethargy—Methotrexate—bone cancer	0.000382	0.00914	CcSEcCtD
Ethosuximide—Leukopenia—Cisplatin—bone cancer	0.000368	0.0088	CcSEcCtD
Ethosuximide—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000366	0.0049	CbGpPWpGaD
Ethosuximide—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000365	0.00489	CbGpPWpGaD
Ethosuximide—Lethargy—Epirubicin—bone cancer	0.000358	0.00855	CcSEcCtD
Ethosuximide—Irritability—Methotrexate—bone cancer	0.000358	0.00855	CcSEcCtD
Ethosuximide—Ataxia—Methotrexate—bone cancer	0.000352	0.00842	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000348	0.00831	CcSEcCtD
Ethosuximide—Breast disorder—Methotrexate—bone cancer	0.000339	0.00809	CcSEcCtD
Ethosuximide—Lethargy—Doxorubicin—bone cancer	0.000331	0.00791	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—NT5C3A—bone cancer	0.000331	0.00443	CbGpPWpGaD
Ethosuximide—Ataxia—Epirubicin—bone cancer	0.00033	0.00788	CcSEcCtD
Ethosuximide—Nervous system disorder—Cisplatin—bone cancer	0.000329	0.00787	CcSEcCtD
Ethosuximide—Skin disorder—Cisplatin—bone cancer	0.000326	0.00779	CcSEcCtD
Ethosuximide—Eosinophilia—Methotrexate—bone cancer	0.000321	0.00766	CcSEcCtD
Ethosuximide—Abdominal pain upper—Epirubicin—bone cancer	0.00032	0.00765	CcSEcCtD
Ethosuximide—Anorexia—Cisplatin—bone cancer	0.00032	0.00765	CcSEcCtD
Ethosuximide—Breast disorder—Epirubicin—bone cancer	0.000317	0.00757	CcSEcCtD
Ethosuximide—Abdominal discomfort—Methotrexate—bone cancer	0.00031	0.00742	CcSEcCtD
Ethosuximide—Pancytopenia—Methotrexate—bone cancer	0.000307	0.00735	CcSEcCtD
Ethosuximide—Ataxia—Doxorubicin—bone cancer	0.000305	0.00729	CcSEcCtD
Ethosuximide—Eosinophilia—Epirubicin—bone cancer	0.0003	0.00717	CcSEcCtD
Ethosuximide—Abdominal pain upper—Doxorubicin—bone cancer	0.000296	0.00708	CcSEcCtD
Ethosuximide—Breast disorder—Doxorubicin—bone cancer	0.000293	0.00701	CcSEcCtD
Ethosuximide—Decreased appetite—Cisplatin—bone cancer	0.000292	0.00697	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Cisplatin—bone cancer	0.00029	0.00692	CcSEcCtD
Ethosuximide—Drowsiness—Methotrexate—bone cancer	0.000289	0.0069	CcSEcCtD
Ethosuximide—Pancytopenia—Epirubicin—bone cancer	0.000288	0.00688	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000286	0.00684	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—MET—bone cancer	0.000279	0.00374	CbGpPWpGaD
Ethosuximide—Eosinophilia—Doxorubicin—bone cancer	0.000278	0.00664	CcSEcCtD
Ethosuximide—Haematuria—Methotrexate—bone cancer	0.000275	0.00658	CcSEcCtD
Ethosuximide—Weight decreased—Epirubicin—bone cancer	0.000274	0.00655	CcSEcCtD
Ethosuximide—Drowsiness—Epirubicin—bone cancer	0.00027	0.00646	CcSEcCtD
Ethosuximide—Agranulocytosis—Methotrexate—bone cancer	0.000269	0.00644	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000268	0.00359	CbGpPWpGaD
Ethosuximide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000268	0.0064	CcSEcCtD
Ethosuximide—Pancytopenia—Doxorubicin—bone cancer	0.000266	0.00636	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000265	0.00354	CbGpPWpGaD
Ethosuximide—Haematuria—Epirubicin—bone cancer	0.000258	0.00616	CcSEcCtD
Ethosuximide—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000257	0.00343	CbGpPWpGaD
Ethosuximide—Urinary tract disorder—Methotrexate—bone cancer	0.000256	0.00612	CcSEcCtD
Ethosuximide—Urethral disorder—Methotrexate—bone cancer	0.000254	0.00607	CcSEcCtD
Ethosuximide—Weight decreased—Doxorubicin—bone cancer	0.000254	0.00606	CcSEcCtD
Ethosuximide—Agranulocytosis—Epirubicin—bone cancer	0.000252	0.00603	CcSEcCtD
Ethosuximide—Drowsiness—Doxorubicin—bone cancer	0.00025	0.00598	CcSEcCtD
Ethosuximide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000248	0.00592	CcSEcCtD
Ethosuximide—Hypersensitivity—Cisplatin—bone cancer	0.000247	0.00591	CcSEcCtD
Ethosuximide—Erythema multiforme—Methotrexate—bone cancer	0.000245	0.00586	CcSEcCtD
Ethosuximide—Eye disorder—Methotrexate—bone cancer	0.000242	0.00579	CcSEcCtD
Ethosuximide—Asthenia—Cisplatin—bone cancer	0.000241	0.00575	CcSEcCtD
Ethosuximide—Urinary tract disorder—Epirubicin—bone cancer	0.00024	0.00573	CcSEcCtD
Ethosuximide—Haematuria—Doxorubicin—bone cancer	0.000238	0.0057	CcSEcCtD
Ethosuximide—Connective tissue disorder—Epirubicin—bone cancer	0.000238	0.0057	CcSEcCtD
Ethosuximide—Urethral disorder—Epirubicin—bone cancer	0.000238	0.00568	CcSEcCtD
Ethosuximide—Immune system disorder—Methotrexate—bone cancer	0.000234	0.0056	CcSEcCtD
Ethosuximide—Mediastinal disorder—Methotrexate—bone cancer	0.000234	0.00558	CcSEcCtD
Ethosuximide—Agranulocytosis—Doxorubicin—bone cancer	0.000233	0.00558	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—MMP2—bone cancer	0.000233	0.00312	CbGpPWpGaD
Ethosuximide—Diarrhoea—Cisplatin—bone cancer	0.00023	0.00549	CcSEcCtD
Ethosuximide—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.00023	0.00307	CbGpPWpGaD
Ethosuximide—Erythema multiforme—Epirubicin—bone cancer	0.000229	0.00548	CcSEcCtD
Ethosuximide—Mental disorder—Methotrexate—bone cancer	0.000227	0.00543	CcSEcCtD
Ethosuximide—Eye disorder—Epirubicin—bone cancer	0.000227	0.00542	CcSEcCtD
Ethosuximide—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000226	0.00303	CbGpPWpGaD
Ethosuximide—Malnutrition—Methotrexate—bone cancer	0.000226	0.00539	CcSEcCtD
Ethosuximide—Urinary tract disorder—Doxorubicin—bone cancer	0.000222	0.0053	CcSEcCtD
Ethosuximide—Connective tissue disorder—Doxorubicin—bone cancer	0.000221	0.00527	CcSEcCtD
Ethosuximide—Urethral disorder—Doxorubicin—bone cancer	0.00022	0.00526	CcSEcCtD
Ethosuximide—Immune system disorder—Epirubicin—bone cancer	0.000219	0.00524	CcSEcCtD
Ethosuximide—Mediastinal disorder—Epirubicin—bone cancer	0.000219	0.00523	CcSEcCtD
Ethosuximide—Vomiting—Cisplatin—bone cancer	0.000213	0.0051	CcSEcCtD
Ethosuximide—Mental disorder—Epirubicin—bone cancer	0.000212	0.00508	CcSEcCtD
Ethosuximide—Erythema multiforme—Doxorubicin—bone cancer	0.000212	0.00507	CcSEcCtD
Ethosuximide—Rash—Cisplatin—bone cancer	0.000212	0.00506	CcSEcCtD
Ethosuximide—Dermatitis—Cisplatin—bone cancer	0.000211	0.00505	CcSEcCtD
Ethosuximide—Malnutrition—Epirubicin—bone cancer	0.000211	0.00505	CcSEcCtD
Ethosuximide—Eye disorder—Doxorubicin—bone cancer	0.00021	0.00501	CcSEcCtD
Ethosuximide—Muscle spasms—Epirubicin—bone cancer	0.000203	0.00485	CcSEcCtD
Ethosuximide—Immune system disorder—Doxorubicin—bone cancer	0.000203	0.00485	CcSEcCtD
Ethosuximide—Mediastinal disorder—Doxorubicin—bone cancer	0.000202	0.00483	CcSEcCtD
Ethosuximide—Leukopenia—Methotrexate—bone cancer	0.000202	0.00483	CcSEcCtD
Ethosuximide—Nausea—Cisplatin—bone cancer	0.000199	0.00476	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—MET—bone cancer	0.000199	0.00267	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—CDK4—bone cancer	0.000199	0.00267	CbGpPWpGaD
Ethosuximide—Mental disorder—Doxorubicin—bone cancer	0.000197	0.0047	CcSEcCtD
Ethosuximide—Malnutrition—Doxorubicin—bone cancer	0.000195	0.00467	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—CYP3A4—bone cancer	0.000194	0.0026	CbGpPWpGaD
Ethosuximide—Agitation—Epirubicin—bone cancer	0.000194	0.00464	CcSEcCtD
Ethosuximide—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000194	0.0026	CbGpPWpGaD
Ethosuximide—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	0.000192	0.00257	CbGpPWpGaD
Ethosuximide—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000191	0.00256	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000191	0.00456	CcSEcCtD
Ethosuximide—Leukopenia—Epirubicin—bone cancer	0.000189	0.00452	CcSEcCtD
Ethosuximide—Muscle spasms—Doxorubicin—bone cancer	0.000188	0.00449	CcSEcCtD
Ethosuximide—Nervous system disorder—Methotrexate—bone cancer	0.000181	0.00432	CcSEcCtD
Ethosuximide—Agitation—Doxorubicin—bone cancer	0.00018	0.00429	CcSEcCtD
Ethosuximide—Skin disorder—Methotrexate—bone cancer	0.000179	0.00428	CcSEcCtD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000178	0.00427	CcSEcCtD
Ethosuximide—Anorexia—Methotrexate—bone cancer	0.000175	0.0042	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—MMP9—bone cancer	0.000175	0.00234	CbGpPWpGaD
Ethosuximide—Leukopenia—Doxorubicin—bone cancer	0.000175	0.00418	CcSEcCtD
Ethosuximide—Nervous system disorder—Epirubicin—bone cancer	0.000169	0.00404	CcSEcCtD
Ethosuximide—Skin disorder—Epirubicin—bone cancer	0.000167	0.004	CcSEcCtD
Ethosuximide—CYP2E1—Biological oxidations—GSTP1—bone cancer	0.000166	0.00223	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP2—bone cancer	0.000166	0.00222	CbGpPWpGaD
Ethosuximide—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000166	0.00222	CbGpPWpGaD
Ethosuximide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000165	0.00395	CcSEcCtD
Ethosuximide—Anorexia—Epirubicin—bone cancer	0.000164	0.00393	CcSEcCtD
Ethosuximide—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	0.000164	0.00219	CbGpPWpGaD
Ethosuximide—Somnolence—Methotrexate—bone cancer	0.000164	0.00391	CcSEcCtD
Ethosuximide—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000164	0.00219	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000161	0.00215	CbGpPWpGaD
Ethosuximide—Decreased appetite—Methotrexate—bone cancer	0.00016	0.00383	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000159	0.0038	CcSEcCtD
Ethosuximide—Fatigue—Methotrexate—bone cancer	0.000159	0.00379	CcSEcCtD
Ethosuximide—Nervous system disorder—Doxorubicin—bone cancer	0.000156	0.00374	CcSEcCtD
Ethosuximide—Skin disorder—Doxorubicin—bone cancer	0.000155	0.0037	CcSEcCtD
Ethosuximide—Somnolence—Epirubicin—bone cancer	0.000153	0.00366	CcSEcCtD
Ethosuximide—Anorexia—Doxorubicin—bone cancer	0.000152	0.00363	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Methotrexate—bone cancer	0.000151	0.0036	CcSEcCtD
Ethosuximide—Decreased appetite—Epirubicin—bone cancer	0.00015	0.00358	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000149	0.00356	CcSEcCtD
Ethosuximide—Fatigue—Epirubicin—bone cancer	0.000149	0.00355	CcSEcCtD
Ethosuximide—Urticaria—Methotrexate—bone cancer	0.000146	0.0035	CcSEcCtD
Ethosuximide—Abdominal pain—Methotrexate—bone cancer	0.000146	0.00348	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—ENO2—bone cancer	0.000145	0.00194	CbGpPWpGaD
Ethosuximide—Somnolence—Doxorubicin—bone cancer	0.000142	0.00339	CcSEcCtD
Ethosuximide—CACNA1G—Axon guidance—EGFR—bone cancer	0.000141	0.00189	CbGpPWpGaD
Ethosuximide—Gastrointestinal pain—Epirubicin—bone cancer	0.000141	0.00337	CcSEcCtD
Ethosuximide—Decreased appetite—Doxorubicin—bone cancer	0.000139	0.00331	CcSEcCtD
Ethosuximide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000138	0.00329	CcSEcCtD
Ethosuximide—Fatigue—Doxorubicin—bone cancer	0.000137	0.00329	CcSEcCtD
Ethosuximide—Urticaria—Epirubicin—bone cancer	0.000137	0.00327	CcSEcCtD
Ethosuximide—Abdominal pain—Epirubicin—bone cancer	0.000136	0.00326	CcSEcCtD
Ethosuximide—Hypersensitivity—Methotrexate—bone cancer	0.000136	0.00324	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—DHFR—bone cancer	0.000134	0.0018	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—NT5C3A—bone cancer	0.000133	0.00178	CbGpPWpGaD
Ethosuximide—Asthenia—Methotrexate—bone cancer	0.000132	0.00316	CcSEcCtD
Ethosuximide—Gastrointestinal pain—Doxorubicin—bone cancer	0.00013	0.00312	CcSEcCtD
Ethosuximide—Hypersensitivity—Epirubicin—bone cancer	0.000127	0.00303	CcSEcCtD
Ethosuximide—Urticaria—Doxorubicin—bone cancer	0.000127	0.00303	CcSEcCtD
Ethosuximide—Abdominal pain—Doxorubicin—bone cancer	0.000126	0.00301	CcSEcCtD
Ethosuximide—Diarrhoea—Methotrexate—bone cancer	0.000126	0.00301	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—GNA11—bone cancer	0.000126	0.00168	CbGpPWpGaD
Ethosuximide—CACNA1G—Developmental Biology—MMP9—bone cancer	0.000125	0.00167	CbGpPWpGaD
Ethosuximide—Asthenia—Epirubicin—bone cancer	0.000124	0.00296	CcSEcCtD
Ethosuximide—Dizziness—Methotrexate—bone cancer	0.000122	0.00291	CcSEcCtD
Ethosuximide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000119	0.00159	CbGpPWpGaD
Ethosuximide—Diarrhoea—Epirubicin—bone cancer	0.000118	0.00282	CcSEcCtD
Ethosuximide—Hypersensitivity—Doxorubicin—bone cancer	0.000117	0.00281	CcSEcCtD
Ethosuximide—Vomiting—Methotrexate—bone cancer	0.000117	0.0028	CcSEcCtD
Ethosuximide—CYP2E1—Metabolism—NDUFA12—bone cancer	0.000117	0.00156	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NDUFA12—bone cancer	0.000116	0.00156	CbGpPWpGaD
Ethosuximide—Rash—Methotrexate—bone cancer	0.000116	0.00278	CcSEcCtD
Ethosuximide—Dermatitis—Methotrexate—bone cancer	0.000116	0.00277	CcSEcCtD
Ethosuximide—Headache—Methotrexate—bone cancer	0.000115	0.00276	CcSEcCtD
Ethosuximide—Asthenia—Doxorubicin—bone cancer	0.000114	0.00273	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—CYP3A4—bone cancer	0.000114	0.00153	CbGpPWpGaD
Ethosuximide—Dizziness—Epirubicin—bone cancer	0.000114	0.00272	CcSEcCtD
Ethosuximide—Vomiting—Epirubicin—bone cancer	0.00011	0.00262	CcSEcCtD
Ethosuximide—Nausea—Methotrexate—bone cancer	0.000109	0.00261	CcSEcCtD
Ethosuximide—Diarrhoea—Doxorubicin—bone cancer	0.000109	0.00261	CcSEcCtD
Ethosuximide—Rash—Epirubicin—bone cancer	0.000109	0.0026	CcSEcCtD
Ethosuximide—Dermatitis—Epirubicin—bone cancer	0.000109	0.00259	CcSEcCtD
Ethosuximide—Headache—Epirubicin—bone cancer	0.000108	0.00258	CcSEcCtD
Ethosuximide—Dizziness—Doxorubicin—bone cancer	0.000105	0.00252	CcSEcCtD
Ethosuximide—Nausea—Epirubicin—bone cancer	0.000102	0.00245	CcSEcCtD
Ethosuximide—Vomiting—Doxorubicin—bone cancer	0.000101	0.00242	CcSEcCtD
Ethosuximide—CACNA1G—Developmental Biology—EGFR—bone cancer	0.000101	0.00135	CbGpPWpGaD
Ethosuximide—Rash—Doxorubicin—bone cancer	0.000101	0.0024	CcSEcCtD
Ethosuximide—Dermatitis—Doxorubicin—bone cancer	0.0001	0.0024	CcSEcCtD
Ethosuximide—Headache—Doxorubicin—bone cancer	9.99e-05	0.00239	CcSEcCtD
Ethosuximide—CYP3A43—Metabolism—GSTP1—bone cancer	9.74e-05	0.0013	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—NT5C3A—bone cancer	9.65e-05	0.00129	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—NT5C3A—bone cancer	9.63e-05	0.00129	CbGpPWpGaD
Ethosuximide—Nausea—Doxorubicin—bone cancer	9.47e-05	0.00226	CcSEcCtD
Ethosuximide—CYP3A4—Biological oxidations—GSTP1—bone cancer	7.71e-05	0.00103	CbGpPWpGaD
Ethosuximide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	7.61e-05	0.00102	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—ENO2—bone cancer	5.84e-05	0.000781	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—DHFR—bone cancer	5.42e-05	0.000725	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NDUFA12—bone cancer	5.41e-05	0.000724	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GNA11—bone cancer	5.06e-05	0.000678	CbGpPWpGaD
Ethosuximide—CYP3A43—Metabolism—PTGS2—bone cancer	5.05e-05	0.000676	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—CYP3A4—bone cancer	4.59e-05	0.000614	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—NT5C3A—bone cancer	4.48e-05	0.0006	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—ENO2—bone cancer	4.23e-05	0.000566	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—ENO2—bone cancer	4.22e-05	0.000565	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—GSTP1—bone cancer	3.93e-05	0.000525	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—DHFR—bone cancer	3.92e-05	0.000525	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—DHFR—bone cancer	3.92e-05	0.000524	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GNA11—bone cancer	3.67e-05	0.000491	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GNA11—bone cancer	3.66e-05	0.00049	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—CYP3A4—bone cancer	3.32e-05	0.000445	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—CYP3A4—bone cancer	3.32e-05	0.000444	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—GSTP1—bone cancer	2.84e-05	0.000381	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—GSTP1—bone cancer	2.84e-05	0.00038	CbGpPWpGaD
Ethosuximide—CYP3A7—Metabolism—PTGS2—bone cancer	2.03e-05	0.000272	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—ENO2—bone cancer	1.96e-05	0.000263	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—DHFR—bone cancer	1.82e-05	0.000244	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GNA11—bone cancer	1.7e-05	0.000228	CbGpPWpGaD
Ethosuximide—CYP2E1—Metabolism—PTGS2—bone cancer	1.47e-05	0.000197	CbGpPWpGaD
Ethosuximide—CYP3A5—Metabolism—PTGS2—bone cancer	1.47e-05	0.000197	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—GSTP1—bone cancer	1.32e-05	0.000177	CbGpPWpGaD
Ethosuximide—CYP3A4—Metabolism—PTGS2—bone cancer	6.83e-06	9.15e-05	CbGpPWpGaD
